Beruflich Dokumente
Kultur Dokumente
Submitted by=
Pinkey Chowdhury (IM/15270) Nilufar Sharmin (IM/15262) Jobayda Akther (HRM/152 Shirin Akther (IM/15261) MBA
Department of Management Studies, Faculty DATE OF SUBMISSION: 20 January,2012. of Business Administration, University of Chittagong.
SL NO. 1 2
Contents
Page
3 4 5 6 7 8 9 10
Contact Information
980 Great West Rd., Brentford London TW8 9GS, United Kingdom +44-20-8047-5000
Financial Highlights Fiscal Year End: Revenue (2010): Revenue Growth (1 yr): Employees (2010): Employee Growth (1 yr): December 43916.70 M (-2.80%) 96,500 (-3.40%)
Key People Chairman: Sir Christopher Charles (Chris) Gent CEO and Director: Andrew Witty SVP Global Communications: Philip (Phil) Thomson
Top Competitors
History of GlaxoSmithKline
GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and healthrelated consumer products. GSKs principal pharmaceutical products include medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatalogicals and vaccines. The Companys segments include Pharmaceuticals and Consumer Healthcare. On January 30, 2009, GSK acquired Bristol Myers Squibb Pakistan (Private) Limited. On March 31, 2009, it acquired from UCB S.A. On April 21, 2009, the Company acquired AZ Tika, a wholly owned subsidiary of Astra Zeneca plc. On July 22, 2009, the Company acquired Stiefel Laboratories, Inc. On October 30, 2009, GSK acquired Pfizer Inc.s HIV business and combined it with its own HIV business to form ViiV Healthcare Limited. On November 10, 2009, GSK acquired the Algerian pharmaceutical, manufacturing and distribution group, Laboratoire Pharmaceutique Algerien. On December 18, 2009, GSK acquired NovaMin Technology Inc. In June 2010, the Company acquired Laboratorios Phoenix S.A.C.yF. In February 2011, the Company sold its entire holding in Quest Diagnostics Inc.
Manufacturing solutions We provide all the advantages you need for a successful contract manufacturing partnership: Cost-effective commercial investment Considerable corporate resources Cost-effective operational scale Rapid development of products Highly experienced professionals Leading-edge facilities Tradition of innovation Proven operational excellence Biopharm successes Proven track record of multiple successful technology transfers of both clinical and commercial products internally and externally FDA multi-product licensed facilities Proficient in supporting numerous biopharmaceutical technology platforms
Business strategy
Geographic Presence
GSK is present in more than 100 countries across the World. The major geographical division of GSK is US , Europe,Asia pacific/Japan and Emerging Market.
Product Portfolio
Respiratory
Seretide/Advair, a combination of Serevent and Flixotide, offers a long-acting bronchodilator and an anti-inflammatory in a single inhaler. It is approved for the treatment of asthma and COPD. Flixotide/Flovent and Beclovent are inhaled steroids for the treatment of inflammation associated with asthma and COPD. Serevent is a long-acting bronchodilator used to treat asthma and COPD, and Ventolin is a selective short-acting bronchodilator used to treat bronchospasm. Veramyst/Avamys, Flixonase/Flonase and Beconase are intra-nasal preparations for the treatment of perennial and seasonal rhinitis.
Central nervous system (CNS)
Seroxat/Paxil is a selective serotonin re-uptake inhibitor (SSRI) for the treatment of major depressive disorder, panic, obsessive compulsive disorder, post traumatic stress disorder, social anxiety disorder, premenstrual dysphoric disorder, and general anxiety disorder. A controlled release forumulation, Paxil CR, is available in the USA. Wellbutrin is an anti-depressant, available in the USA and many European and international markets in normal, sustained-release (SR) and once daily (XL) formulations. Imigran/Imitrex is a 5HT1 receptor agonist used for the treatment of severe or frequent migraine and cluster headache, and has become the reference product in this sector. Naramig/Amerge is also a 5HT1 receptor agonist indicated for the treatment of migraine. Lamictal, a well established treatment for epilepsy, is also indicated for bipolar disorder. Requip is a specific dopamine D2/D3 receptor agonist indicated for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS).
Anti-virals
In November 2009, GSK's HIV/AIDS medicines became the property of ViiV Healthcare. Zeffix has been approved for marketing in the USA, Europe, China and other markets for the treatment of chronic hepatitis B. Valtrex is a treatment for episodic genital herpes as well as the long term suppression and reduction of transmission of genital herpes, zoster (shingles), cold sores and chicken pox. Valtrex supersedes Zovirax , which is also used to treat herpes infections. Relenza is an anti-viral used to prevent and treat influenza.
Anti-bacterials
Augmentin is a broad-spectrum antibiotic suitable for the treatment of a wide range of common bacterial infections and is particularly effective against respiratory tract infections. Augmentin
ES-600 is an extra strength suspension specifically designed to treat children with recurrent or persistent middle ear infections. Augmentin XR is an extended release formulation for the treatment of patients with community acquired pneumonia or acute bacterial sinusitis. Altabax/Altargo, approved in 2007 for the topical treatment of certain bacterial skin infections, represents the first new class of topical antibiotics approved by the FDA in nearly two decades. Ceftin/Zinnat is an oral antibiotic used primarily for community acquired infections of the lower respiratory tract.
Metabolic
Avandia is a potent insulin sensitising agent which acts on the underlying pathophysiology of type 2 diabetes. For more information about Avandia and associated products, visit the Avandia section of this website. Bonviva/Boniva is a long acting bisphosphonate available in once-monthly oral and quarterly injection forms for the treatment of osteoporosis (co-promoted with Roche)
Vaccines
GlaxoSmithKline markets over 30 vaccines worldwide, of which more than half are combination vaccines to protect children, adolescents and/or adults against up to six diseases at the same time. Cervarix is a vaccine intended to protect females against the diseases caused by infection with Human Papillomavirus (HPV) types 16 and 18. These diseases include cervical cancer and precancerous cervical lesions. Infanrix is a range of paediatric vaccine combinations. Infanrix provides protection against diphtheria, tetanus and pertussis (whooping cough). Infanrix penta (Europe) / Pediarix (USA and Canada) provides additional protection against hepatitis B and polio, and Infanrix hexa further adds protection against Haemophilus influenzae type b, which causes meningitis. Boostrix is available to add protection against pertussis (whooping cough) to the routine tetanus/diphtheria booster administered to teenagers. In GSK's hepatitus range, Havrix protects against hepatitis A and Engerix-B against hepatitis B. Twinrix is the only available combined hepatitis A and B vaccine, protecting against both diseases with one vaccine and available in both adult and paediatric strengths. In Europe, FENDrix, a vaccine to prevent hepatitis B in patients with renal insufficiency including high-risk groups such as pre-haemodialysis and haemodialysis patients, is available from 15 years of age onwards. GSK added Fluviral to its portfolio of products when it acquired the Canadian vaccine manufacturer ID Biomedical Corporation in December 2005. Fluviral is marketed in Canada and, following FDA approval, the USA where it is approved for the active immunisation of adults 18 years and older against infl uenza disease under the brand FluLaval. Fluviral and FluLaval add to Fluarix GSKs seasonal flu vaccine, which is distributed in 79 countries including the USA. GSK also markets Priorix, a measles, mumps and rubella vaccine, Typherix, a vaccine for protection against typhoid fever, and Varilrix, a vaccine against varicella or chicken pox. Priorix-
Tetra, GSKs new combination vaccine to prevent measles, mumps, rubella and varicella (MMRV) was first launched in Germany in August 2006. In addition, the Group markets a range of vaccines to prevent meningitis under the umbrella name Mencevax. GSKs new Hib- MenC vaccine, Menitorix is now available in the UK. GSKs meningitis vaccine portfolio will be complemented by new meningitis conjugate vaccines in the near future. As part of its paediatric franchise, GSK continued to roll out the launch of its vaccine against rotavirus induced gastroenteritis, Rotarix, which is now launched in 90 countries worldwide. Rotavirus vaccination has been included in the national vaccination calendar of fi ve Latin American countries where Rotarix will be available free at public health clinics, as part of governmental paediatric immunisation programmes.
Oncology and emesis Tykerb is an oral treatment for patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab. Tykerb was approved in the USA in 2007 and is now available in Europe, where is is known as Tyverb. Hycamtin is a second line treatment for ovarian, cervical and small cell lung cancer. Bexxar is a treatment for patients with CD20 follicular, non-Hodgkins lymphoma with and without transformation whose disease is refractory to rituximab and who have relapsed following chemotherapy. Arranon (nelarabine) a treatment for patients with T-cell acute lymphoblastic leukaemia and Tcell lymphoblastic lymphoma. Zofran is used to prevent nausea and vomiting associated with chemotherapy and radiotherapy for cancer, and is available in both oral and injectable forms. It is also approved for use in the prevention and treatment of post-operative nausea and vomiting.
Cardiovascular and urogenital
Coreg is an alpha/beta blocker which has been proven to be effective in treating patients with mild, moderate and severe heart failure, heart attack or hypertension. GSK has sole marketing rights in the USA and Canada. A controlled release formulation, Coreg CR is also available in the USA. Generic versions of Coreg are available in the USA and Canada. Levitra is a PDE-5 inhibitor indicated for male erectile dysfunction. GSK has co-promotion rights in the USA and more than 20 other markets. Avodart is a 5-ARI inhibitor currently indicated for benign prostatic hyperplasia. A large clinical study is underway examining its efficacy in reducing the risk of prostate cancer. Vesicare is an anti-muscarinic indicated for overactive bladder. GSK has co-promotion rights with Astellas in the USA. Its major competitors are Detrol LA, Ditropan XL/generic oxybutynin, and Enablex. Arixtra, a selective Factor Xa inhibitor, is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of DVT and PE in patients
undergoing major orthopaedic surgery, abdominal surgery and acutely ill medical patients (EU only). Also in the EU, Arixtra is indicated for the treatment of patients with acute coronary (unstable angina, NSTEMI and STEMI). Fraxiparine is a low-molecular weight heparin indicated for prophylaxis of thromboembolic disorders (particularly deep vein thrombosis and pulmonary embolism) in general surgery and in orthopedic surgery, treatment of deep vein thrombosis and prevention of clotting during haemodialysis. Integrilin is a GP IIb-IIIa inhibitor, approved in the EU for the prevention of early myocardial infarction in patients with unstable angina or non-Q-wave MI.
Dermatologicals
The dermatology portfolio includes heritage GSK products (e.g. Bacroban, Duac and Zovirax) and those acquired through business acquisitions, principally Stiefel in July 2009.
Other
This category includes Betnovate, the higher potency Dermovate and the newer Cutivate, which are anti-inflammatory steroid products used to treat skin diseases such as eczema and psoriasis, Relafen, a non-steroidal anti-inflammatory drug for the treatment of arthritis, and Zantac, for the treatment of peptic ulcer disease and a range of gastric acid related disorders. Employee Distribution
Figure:Employee distribution
Business Summary GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, anti-bacterials, metabolic, vaccines, oncology and emesis, cardiovascular and urogenital, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 30 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joint pain, fever, and cold symptoms; Gaviscon, a range of antacid products that relieve heartburn due to acid reflux; alli, a weight loss product; and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes for the prevention of dental sensitivity; Biotene, a mouthwash and gel to treat dry mouth; and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration; Horlicks, a malted, milk-based drink and food for nutrition application; and Ribena, a blackcurrant juice-based drink, as well as markets skincare products. GlaxoSmithKline plc was founded in 1999 and is headquartered in Brentford, United Kingdom.
Products of GlaxoSmithKline
Pharmaceutical products
GSKs principal pharmaceutical products are directed to nine therapeutic areas, including dermatologicals, respiratory, central nervous system, anti-virals, metabolic, vaccines, cardiovascular and urogenital, anti-bacterials, and oncology and emesis. Its products for respiratory therapeutic area include Seretide/Advair, Flixotide/Flovent, Serevent, Veramyst and Flixonase/Flonase. Its products for anti-virals include Epzicom/Kivexa, Combivir, Trizivir, Agenerase, Lexiva, Epivir, Ziagen, Valtrex, Zeffix and Relenza. The products for central nervous system include Lamictal, Imigran/lmitrex, Seroxat/Paxil, Wellbutrin SR, Requip and Treximet. The Companys products for cardiovascular and urogenital areas include Avodart, Lovaza, Coreg CR, Fraxiparine, Arixtra and Vesicare. Its Metabolic products include Avandia and Avandamet. Anti-bacterials include products, such as Augmentin and Altabax. Oncology and emesis products include Arzerra, Hycamtin, Promacta/Revolade, Tykerb/Tyverb and Votrient. The Companys products for vaccines include Infanrix/Pediarix, Fluarix, FluLaval, Cervarix, Synflorix and Rotarix. The Company competes with Abbott Laboratories, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche Holdings and Sanofi-Aventis.
Market Overview
Market Share
GSK DTPw combos DTPa combos MMR HEP a Rotavirus Meningococcal Influenza Pneumococcal HPV Malaria Dengue Y Y Y Y Y Y Y Y Y D D
Merck
Sanofi Y Y
Pfizer
Novartis Y
Y Y Y
Y Y
Y Y Y Y
D Y
D= In Developement
Clinical Trial
Neisseriamenhibrix meningitis C , haemophilus Heptavalent Influenza type b, Diptheria, HepB, Tetanus, pertussis II combination vacine and poliomyelitis disease prophylaxis MMR S.Pneumoniae pediatric next Measeles mumps rebella propylaxis Streptococcus pneumoniae disease prophylaxis II(US) II
generation Mosquirix Nimenrix Malaria prophylaxis Neisseria meningtis groups A,C,W,Y Neisseria meningtis group C & Y & haemophilus Influenza type b III Submit ed Submit ed
Menhibrix
Other Vaccine
Indication Pandemic influenza prophylaxis HIV prophylaxis HIV immunotherapy TB prophylaxis Seasonal influenza prophylaxis Herpes Zoster prevention Pre pandemic and pandemic influenza prophylaxis Pandemic Influeza Prophylaxis
Phase I I II II III
Zoster
III
Submitted
Pumariz
Submitted
manufacturer by establishing its own manufacturing unit in Chittagong in1967.The facility till date is considered as one of the centers of Excellence in Global manufacturing and supply network of the Group. The global corporate mergers and acquisitions has seen the evolution of the companies identity in the past 6 decades.In line with mergers and acquisitions the identity changed from Glaxo to Glaxo welcome Bangladesh Limited during 2002 After mergers with SmithklineBeecham in December 2000.The mega merger of the company enables it to deliver cutting edge advancement in healthcare solutions.The relentless commitment,setting of standard of ethical standards and quality backed leading edge technology of the company has built in a strong relationship between stakeholders and GSK Bangladesh.With the ever committed 615 numbers of personnel all over the country GSK Bangladesh,Which now comprises of boyh pharma and Consumer,Continually strive to meet the GlaxoSmithKline mission to improve the quality of human life by ensuring healthcare products ,healthdrinks and different corporate social responsibility programs. GSK is committed to developing new and effective healthcare solutions.The values on which the group was founded have always inspired growth and will continue to do so in times to come.
1956: Second branch in East Pakistan was opened at Motijheel, Dhaka. 1960-1969: Permission for establishment of a factory at Chittagong was obtained from the Govt. land for Fauzderhat factory was purchased. Plan for factory building at Fauzderhat was passed by Chittagong Divisional Commissioner in 1962.In 1966,Third branch was opened in Khan Jahan Ali Road ,Khulna.East Pakistan head office was established headed by One resident Director.In1967 Chittagong factory went into production. Permission for packing of 1800 tons baby food and 900 tons Glaxose D was granted by Govt. 1970-1979: In 1970,packing of Glaxose-D started. All establishment of Glaxo laboratories (Pakistan)Ltd. In the then East Pakistan was vested in the abandoned properties of the Government. In 1973,Realeased from abandoned properties and permission was given by the Government to form a company in Bangladesh. Packing of milk food commenced.Glaxo Bangladesh Limited was incorporated and the first depot was opened at Bogra.Depots at Barisal,Mymensingh and Sylhet was opened. 1980-1989: In 1980,sales depots at Comilla,Pabna,Narayanganj and Rangpur were opened.To comply with the requirements of Drugs Control Ordinance the company has to discontinue production of all vitamin preparations(Tablet,Syrap,and Injections)and some other products declared as non essential items.Effect on sales was about 25%.Excise duty on medicine was imposed by the Government.In 1983,Sales depots at Rajshahi,Tangai,Faridpur and Dinajpur was opened. The company discontinued packing of baby food. Companys registered was relocated in Dhaka. 1990-1999: Company properties at Paribag and Gulshan Dhaka was sold and Registered office relocated at Chittagong.In1995,Renamed as Glaxo Welcome Bangladesh Limited following the BURROUGHS welcome acquisition. 2000-2009: In 2002, Following the global mega merger with SmithKlineBeechham Identity Changed to GlaxoSmithKline Bangladesh Limited.
transformation project,the PHASE project,The free primary school project,Lymphatic Filirisis project etc.
Recommendation
With respect to GSK , Serum can go in for the following options:
Low cost Manufacturing Strategic Partnership for marketing of Serum Products
Reference:
1.http://www.gsk.com.bd/ 2.